Pular para o conteúdo
Merck
  • Evaluation of two year treatment outcome and limited impact of arginine restriction in a patient with GAMT deficiency.

Evaluation of two year treatment outcome and limited impact of arginine restriction in a patient with GAMT deficiency.

Molecular genetics and metabolism (2011-10-25)
Saadet Mercimek-Mahmutoglu, Mary Dunbar, Andrea Friesen, Susan Garret, Carol Hartnett, Linda Huh, Graham Sinclair, Sylvia Stockler, Stephen Wellington, Petra J W Pouwels, Gajja S Salomons, Cornelis Jakobs
RESUMO

A 4-year-old female with history of developmental regression and autistic features was diagnosed with guanidinoacetate methyltransferase deficiency at age 21 months. Upon treatment, she showed improvements in her developmental milestones, sensorial-neural hearing loss and brain atrophy on cranial-MRI. The creatine/choline ratio increased 82% in basal ganglia and 88% in white matter on cranial MR-spectroscopy. The CSF guanidinoacetate decreased 80% after six months of ornithine and creatine supplementation and an additional 8% after 18 months of additional arginine restricted diet. We report the most favorable clinical and biochemical outcome on treatment in our patient.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Guanidineacetic acid, 99%